Current research into JAK inhibitors – specifially ruxolitinib, pacritinib, and momelotinib

Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses research into JAK inhibitors for myelofibrosis, specifically ruxolitinib, pacritinib, and momelotinib. Ruxolitinb demonstrated positive results in the COMFORT-II trials (NCT00934544), reducing splenomegaly and symptom improvement. Similar results were also seen with pacritinib. There is still no to data on momelotinib from the most recent clinical Phase III trial. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video